Evaxion (EVAX) Up on Upbeat Preclinical S. Aureus Vaccine Data

Evaxion Biotech A/S (EVAX) , along with its undisclosed partner, announced the successful completion of a series of large non-rodent animal infection studies, testing antigens from its investigational EVX-B1 vaccine candidate, which is being developed to treat Staphylococcus aureus (S. aureus) infection.Per the companies, in the completed pre-clinical studies, treatment with EVX-B1 antigens significantly reduced the disease burden. Based on such positive results, Evaxion and its partner are currently discus ...